Drugs / EB-203
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05538949 | Jun → Oct 2022 | — | EyebioKorea, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06487039 | Aug 2024 → Aug 2025 overdue | wet macular degeneration | EyebioKorea, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05538949 ↗ |